Annual Accounts Receivable
$0.00
-$30.00 M-100.00%
December 31, 2023
Summary
- As of February 8, 2025, MRSN annual accounts receivable is $0.00, with the most recent change of -$30.00 million (-100.00%) on December 31, 2023.
- MRSN annual accounts receivable is now -100.00% below its all-time high of $30.00 million, reached on December 31, 2022.
Performance
MRSN Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$1.00 M
-$570.00 K-36.31%
September 30, 2024
Summary
- As of February 8, 2025, MRSN quarterly accounts receivable is $1.00 million, with the most recent change of -$570.00 thousand (-36.31%) on September 30, 2024.
- Over the past year, MRSN quarterly accounts receivable has increased by +$1.00 million (+100.00%).
- MRSN quarterly accounts receivable is now -96.67% below its all-time high of $30.00 million, reached on December 31, 2022.
Performance
MRSN Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
MRSN Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -100.0% | +100.0% |
| 3 y3 years | - | +100.0% |
| 5 y5 years | -100.0% | +100.0% |
MRSN Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -100.0% | at low | -96.7% | -100.0% |
| 5 y | 5-year | -100.0% | at low | -96.7% | -100.0% |
| alltime | all time | -100.0% | at low | -96.7% | -100.0% |
Mersana Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.00 M(-36.3%) |
| Jun 2024 | - | $1.57 M(>+9900.0%) |
| Dec 2023 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2023 | - | $0.00(0.0%) |
| Jun 2023 | - | $0.00(0.0%) |
| Mar 2023 | - | $0.00(-100.0%) |
| Dec 2022 | $30.00 M(>+9900.0%) | $30.00 M(>+9900.0%) |
| Dec 2021 | $0.00 | $0.00(-100.0%) |
| Sep 2019 | - | $298.00 K(+3.5%) |
| Jun 2019 | - | $288.00 K(-38.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $468.00 K(+2.0%) |
| Dec 2018 | $459.00 K(-41.5%) | $459.00 K(-21.7%) |
| Sep 2018 | - | $586.00 K(-65.1%) |
| Jun 2018 | - | $1.68 M(+483.7%) |
| Mar 2018 | - | $288.00 K(-63.3%) |
| Dec 2017 | $784.00 K(-25.4%) | $784.00 K(+7.3%) |
| Sep 2017 | - | $731.00 K(+42.5%) |
| Jun 2017 | - | $513.00 K(-27.9%) |
| Mar 2017 | - | $712.00 K(-32.3%) |
| Dec 2016 | $1.05 M(+64.2%) | $1.05 M |
| Dec 2015 | $640.00 K | - |
FAQ
- What is Mersana Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Mersana Therapeutics?
- What is Mersana Therapeutics annual accounts receivable year-on-year change?
- What is Mersana Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Mersana Therapeutics?
- What is Mersana Therapeutics quarterly accounts receivable year-on-year change?
What is Mersana Therapeutics annual accounts receivable?
The current annual accounts receivable of MRSN is $0.00
What is the all time high annual accounts receivable for Mersana Therapeutics?
Mersana Therapeutics all-time high annual accounts receivable is $30.00 M
What is Mersana Therapeutics annual accounts receivable year-on-year change?
Over the past year, MRSN annual accounts receivable has changed by -$30.00 M (-100.00%)
What is Mersana Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of MRSN is $1.00 M
What is the all time high quarterly accounts receivable for Mersana Therapeutics?
Mersana Therapeutics all-time high quarterly accounts receivable is $30.00 M
What is Mersana Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, MRSN quarterly accounts receivable has changed by +$1.00 M (+100.00%)